(al-gloo-ko-side-ase) ,


(trade name),


(trade name)


Therapeutic: replacement enzyme
Pregnancy Category: B


Myozyme: Replacement enzyme in infantile-onset Pompe disease (alpha glucosidase (GAA) deficiency).Lumizyme: Replacement enzyme in late-onset (non-infantile) Pompe disease in patients without evidence of cardiac hypertrophy.


Replaces alpha-glucosidase. Without this enzyme, glycogen accumulates in tissues including cardiac and skeletal muscles and hepatic tissues, leading to the development of cardiomyopathy, progressive muscle weakness, and impairment of respiratory function.

Therapeutic effects

Improved survival with delayed need for ventilatory support.
Improved lung function and exercise capacity.


Absorption: IV administration results in complete bioavailability.
Distribution: Unknown.
Metabolism and Excretion: Unknown.
Half-life: 2.3–2.5 hr.

Time/action profile

IVunknownend of infusion2 wk


Contraindicated in: None known.
Use Cautiously in: Acute underlying illness (↑ risk of infusion reactions); Obstetric: Use only if clearly needed; Lactation: Lactation; Pediatric: Safety not established in children <1 mo or >3.5 yr (Myozyme) or <8 yr (Lumizyme).

Adverse Reactions/Side Effects


  • bradycardia (most frequent)
  • tachycardia (most frequent)


  • respiratory distress failure
  • cough (most frequent)
  • ↓ oxygen saturation (most frequent)
  • tachypnea

Ear, Eye, Nose, Throat

  • blurred vision
  • vertigo


  • constipation (most frequent)
  • diarrhea (most frequent)
  • reflux (most frequent)
  • vomiting (most frequent)


  • necrotizing skin lesions (life-threatening)
  • flushing (most frequent)
  • rash (most frequent)
  • dermatitis (most frequent)
  • urticaria (most frequent)


  • anemia (most frequent)
  • lymphadenopathy

Fluid and Electrolyte

  • edema


  • allergic reactions including anaphylaxis (life-threatening)
  • infusion reactions (life-threatening)
  • fever (most frequent)


Drug-Drug interaction

None noted.


Intravenous (Children 1 mo–3.5 yr) Myozyme—20 mg/kg every 2 wk.
Intravenous (Adults and Children ≥8 yr) Lumizyme—20 mg/kg every 2 wk.


Lyophilized powder for IV administration (requires reconstitution): 50 mg/vial

Nursing implications

Nursing assessment

  • Observe for signs and symptoms of anaphylaxis (rash, pruritus, laryngeal edema, wheezing). Keep epinephrine, an antihistamine, corticosteroids, and resuscitation equipment close by in case of anaphylactic reaction.
  • Monitor for infusion-related reactions (headache, fever, tachycardia, cough, cyanosis, rash, erythema, urticaria, hypotension. Most reactions are managed with antihistamines and/or corticosteroids prior to or during infusions, slowing rate of infusion, and/or early discontinuation if reaction is serious. Infusion reactions may occur any time during or up to 2 hr after infusion and are more likely with higher infusion rates.
  • Monitor cardiorespiratory status continuously during therapy. May cause acute cardiorespiratory failure requiring intubation and inotropic support.
  • Lab Test Considerations: Monitor liver enzymes prior to and periodically during therapy.

Potential Nursing Diagnoses

Ineffective tissue perfusion (Indications)


  • Lumizyme is available only through a restricted distribution program called the LUMIZYME ACE Program due to the potential risk of rapid disease progression in Pompe disease patients less than 8 yrs of age. Only prescribers and healthcare facilities enrolled in the program may prescribe, dispense or administer Lumizyme. Lumizyme may be administered only to patients who are enrolled in and meet all the conditions of the Lumizyme ACE Program. To enroll in the Lumizyme ACE Program call 1-800-745-4447.
  • Intravenous Administration
  • Intermittent Infusion: Determine number of vials required for the dose ordered. If number of vials includes a fraction, round up to next whole number. Allow vials to reach room temperature before reconstitution, approximately 30 min. Reconstitute by slowly injecting 10.3 mL of Sterile Water for Injection to inside wall of each vial. Avoid forceful impact of water on powder to avoid foaming. Tilt and roll each vial gently. Do not invert, swirl, or shake. Protect solution from light. Each vial contains 5 mg/mL with a total extractable dose of 50 mg/10 mL. Solution is clear and may occasionally contain white strands or translucent fibers; do not administer solutions that are discolored or contain particulate matter. Vials are for single use; discard remaining medication. Diluent: Dilute each vial in 100 mL of 0.9% NaCl immediately after reconstitution. Concentration: 0.5–4 mg/mL. Slowly withdraw reconstituted solution from each vial. Remove airspace from infusion bag to minimize particle formation due to sensitivity of medication to air. Add reconstituted solution slowly and directly into 0.9% NaCl solution, not into airspace in bag. Gently invert or massage to mix; do not shake. Use a 0.2 micrometer low-protein binding in-line filter for administration. Administer immediately. Solution may be stored in refrigerator for up to 24hr.
  • Rate: Administer over 4 hr. Using an infusion pump, administer initially at a rate of 1 mg/kg/hr. ↑ rate to 2 mg/kg/hr every 30 min, after tolerance to medication is established, until a maximum rate of 7 mg/kg/hr is reached. Monitor vital signs with each dose ↑. If stable, administer at 7 mg/kg/hr until infusion is completed. Slow or temporarily stop infusion if infusion reactions occur.

Patient/Family Teaching

  • Inform patient that a registry for patients with Pompe disease was established to evaluate long term treatments. Women of childbearing potential are also encouraged to register. For information, visit or call 1-800-745-4447.

Evaluation/Desired Outcomes

  • Improved survival with delayed need for ventilatory support in patients with Pompe disease.
  • Improved lung function and exercise capacity.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
A global Phase 1/2 study (ATB200-02) is ongoing to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AT-GAA as well as the global Phase 3 PROPEL study to assess the efficacy, safety and tolerability of AT-GAA compared to alglucosidase alfa, an enzyme replacement therapy, concluded the companies.
As soon as the diagnosis was confirmed, Myozyme[R] (alglucosidase alfa, Sanofi Genzyme, USA) was initiated for the patient (20 mg/kg, every 2 wk).
duvoglustat hydrochloride + alglucosidase alfa - Drug Profile 50
Our patients were treated with 20 mg/kg IV alglucosidase alfa (Myozyme, provided by Genzyme Corporation) biweekly according to previously published reports [22-25].
The Phase III trial is a randomized, multi-center, multi-national, double-blinded study to compare the efficacy and safety of repeated bi-weekly infusions of neoGAA and alglucosidase alfa in treatment-naive patients with late-onset Pompe disease.
In 2006, the FDA approved an enzyme replacement therapy called Myozyme (Alglucosidase alfa, rhGAA), for people with Pompe disease.
Pregnant women treated with alglucosidase alfa (Myozyme) for Pompe disease can enroll in the Pompe Registry (800-745-4447 x 15500 / / en / healthcare-professionals / pompe-registry.aspx).
Since the end of 2012, enzyme replacement therapy (ERT) (as alglucosidase alfa) has been registered with the Medicines Control Council in South Africa for use in PD patients.
Leslie et al., "Early treatment with alglucosidase alfa prolongs long-term survival of infants with pompe disease," Pediatric Research, vol.
Mecanismo Doencaalvo Nome do farmaco de acao Fabry Betagalsidase TRE Fabry Alfagalsidase TRE Fabry AT1001 Chaperona Gaucher Velaglucerase alfa (glicocerebrosidase TRE produzida em celulas humanas) Gaucher Glicocerebrosidase produzida em TRE celulas vegetais Gaucher Miglustate ISS Gaucher Genz-112638 ISS Gaucher AT2101 Chaperona MPS I Laronidase TRE MPS II Idursulfase TRE MPS VI Galsulfase TRE Niemann-Pick B Esfingomielinase recombinante TRE Niemann-Pick C Miglustate ISS Pompe Alglucosidase alfa([alpha]-glicosidase TRE acida produzida em celulas CHO) Pompe [alfa]-glicosidase acida recombinante TRE produzida a partir do leite de coelhos transgenicos Tay-Sachs (tardia) Miglustate ISS Tay-Sachs (tardia) Pirimetamina Chaperona Registro Doencaalvo Fase de desenvolvimento Anvisa?
Then, in November, the FDA warned of the potential for foreign particle contamination in all lots of the two aforementioned therapies plus Myozyme (alglucosidase alpha) for Pompe disease, Aldurazyme (laronidase) for mucopolysaccharidosis type I and Thyrogen (thyrotropin alpha) for thyroid cancer.